OncoMatch/Clinical Trials/NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Is NCT06059391 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Multi-peptide CMV-Modified Vaccinia Ankara Vaccine and Granulocyte Colony-Stimulating Factor for acute lymphoblastic leukemia.
Treatment: Granulocyte Colony-Stimulating Factor · Hematopoietic Cell Transplantation Conditioning Regimen · Multi-peptide CMV-Modified Vaccinia Ankara Vaccine · Stem Cell Mobilization Therapy — This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem cell transplant. Giving the CMV-MVA triplex vaccine to donors may help prevent CMV infection of patients undergoing stem cell transplantation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Hodgkin Lymphoma
Myeloproliferative Neoplasm
Biomarker criteria
Required: HLA 8/8 (A, B, C, DRB1) high resolution allele matching
RECIPIENTS: Planned related HCT with 8/8 (A, B, C, DRB1) high resolution human leukocyte antigen (HLA) donor allele matching
Prior therapy
Cannot have received: allogeneic transplant
RECIPIENTS: Prior allogeneic (allo) transplant for any condition
Cannot have received: investigational CMV vaccine
RECIPIENTS: Any prior investigational CMV vaccine
Cannot have received: experimental anti-CMV chemotherapy
RECIPIENTS: Experimental anti-CMV chemotherapy in the last 6 months
Lab requirements
Kidney function
Creatinine clearance of 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Liver function
Total bilirubin 2 X upper limit of normal (ULN) (unless has Gilbert's disease); AST 2.5 x ULN; ALT 2.5 x ULN
Cardiac function
Left ventricular ejection fraction (LVEF) 50%
RECIPIENTS: Total bilirubin 2 X upper limit of normal (ULN) (unless has Gilbert's disease); AST 2.5 x ULN; ALT 2.5 x ULN; Creatinine clearance of 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula; Left ventricular ejection fraction (LVEF) 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- Northside Hospital · Atlanta, Georgia
- DFCI/BWH Brigham and Women's Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify